The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antiphospholipid Antibody Syndrome

Antiphospholipid Antibody Syndrome

July 1, 2007 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A recently identified autoimmune disorder, antiphospholipid antibody syndrome (APS) mainly affects young women between age 30 and 40. Those affected by APS may otherwise be healthy or have an underlying disease such as systemic lupus erythematosus (SLE).

You Might Also Like
  • Antiphospholipid Syndrome
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
  • Antiphospholipid Antibody Syndrome: Much Remains to be Learned
Explore This Issue
July 2007
Also By This Author
  • How Obamacare Is Expected to Impact Rheumatologists and Their Patients

APS is “an autoimmune disease associated with frequent clotting in arteries and veins and/or fetal losses,” according to fact-sheet author Pier Luigi Meroni, MD, professor of rheumatology at the University of Milan in Italy. “The clotting results from the presence of proteins in the blood called antiphospholipid autoantibodies formed against the person’s own tissues. In circulation, these autoantibodies are able to interfere with some mechanisms of coagulation, leading to clot formation or thrombosis.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

It is not completely clear why patients develop these autoantibodies. Some evidence suggests that environmental factors—such as infections in the presence of a predisposing genetic background—play a role in triggering autoantibody production.

Dr. Meroni also notes that “the need for a long-term oral anticoagulant therapy significantly affects the lifestyle of the patients, creating the need for regular controls for the anticoagulation effect and special attention paid to the diet and to situations at risk of bleeding, such as falls.” Correcting thrombosis risk factors (diabetes, hypertension, hypercholesterolemia, obesity, smoking, and estrogen therapy for menopause or contraception) is mandatory in APS patients and significantly affects lifestyle.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Preventive treatment for obstetrical manifestations—such as heparin injections and low-dose aspirin—is quite effective. The majority of the women can eventually have healthy babies.

For more details on diagnosing, treating, and living with APS—or for information about other patient-education materials—visit www.rheumatology.org/public/factsheets.

Filed Under: From the College Tagged With: Antiphospholipid Antibody Syndrome (APS), Diagnostic Criteria, Hughes Syndrome, PatientsIssue: July 2007

You Might Also Like:
  • Antiphospholipid Syndrome
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
  • Antiphospholipid Antibody Syndrome: Much Remains to be Learned
  • Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)